EN | TR
E-ISSN: 2146-3077
Crimean Congo Hemorrhagic Fever in Eastern Turkey: Epidemiological and Clinical Evaluation
PDF
Cite
Share
Request
Original Investigation
VOLUME: 43 ISSUE: 1
P: 26-29
March 2019

Crimean Congo Hemorrhagic Fever in Eastern Turkey: Epidemiological and Clinical Evaluation

Turkiye Parazitol Derg 2019;43(1):26-29
DOI: 10.4274/tpd.galenos.2019.6142
Ayşe Sağmak Tartar
Şafak Özer Balın
Ayhan Akbulut
Kutbeddin Demirdağ
1. Fırat Üniversitesi, Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji, Elazığ, Türkiye
No information available.
No information available
Received Date: 03.10.2018
Accepted Date: 28.01.2019
Publish Date: 28.03.2019
PDF
Cite
Share
Request

ABSTRACT

Objective:

The present study aimed to evaluate Crimean-Congo Haemorrhagic Fever (CCHF) in patients hospitalized in our hospital.

Methods:

A total of 61 adult patients who were diagnosed as having CCHF between January 2011 and August 2018, in whom the diagnosis was confirmed by detecting virus-specific IgM by ELISA and/or by showing viral RNA by RT-PCR and who were managed at our clinic were evaluated retrospectively for their epidemiological and clinical findings, treatment and prognosis.

Results:

Of the 61 cases, 41 (67.2%) were male and 20 (32.8%) female. The mean age of the patients was 45.31±2.12 years. Sixty (98.4%) patients were living in rural area. Forty four patients (72.1 %) had a tick-bite history. According to months, most of the cases were seen in June, July and May, respectively. Fever, weakness and loss of appetite were the most common complaints of the patients. Treatment of ribavirin was started on the day of admission in all patients. One patient who was admitted in the late period died. The other 60 patients were discharged after being healed.

Conclusions:

Especially during summers when the disease is seen frequently, the history of tick contact should be questioned and tick should be searched in the examination in the patients with suspected clinical findings. A significant number of the patients do not have a known tick contact. Therefore, training meetings should be organized about the symptoms and findings of the disease in the endemic areas and awareness should be raised among the community and the doctors working in emergency services and primary care.

Keywords: Crimean-Congo Haemorrhagic Fever, epidemiology, tick borne disease

References

1
Ergonul O, Celikbaş A, Dokuzoğuz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004;39:284-7.
2
Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005;54:385-9.
3
Peters CJ, Zaki SR. Overview of viral hemorrhagic fevers. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases: Principles, Pathogens, and Practice. Philadelphia, PA: Churchill Livingstone, 2006:726-33.
4
Ergonul O, Battal I. Potential sexual transmission of Crimean- Congo hemorrhagic fever infection. Jpn J Infect Dis 2014;67:137-8.
5
Özkurt Z. Kırım Kongo Kanamalı Ateşi. Yoğun Bakım Dergisi 2007;7:85-90.
6
Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int. J. Antimicrob. Agents 2010;36:43-6.
7
Leblebicioğlu H, Özaras R, Irmak H, Sencan I. Crimean-Congo hemorrhagic fever in Turkey: Current status and future challenges. Antiviral Research J 2016;126:21-34.
8
Yağci-Çağlayik D, Korukluoğlu G, Uyar Y. Seroprevalence and Risk Factors of Crimean-Congo Hemorrhagic Fever in Selected Seven Provinces in Turkey. J Med Virol 2014;86:306-14.
9
Ozkurt Z, Kiki I, Erol S, Erdem F, Yılmaz N, Parlak M, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006;52:207-15.
10
Ertugrul B, Uyar Y, Yavas K, Turan C, Oncu S, Saylak O, et al. An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. Int J Infect Dis 2009;13:431-6.
11
Suntur BM, Hepgüler KS. Kırım Kongo Kanamalı Ateşi: Kütahya’dan iki olgu sunumu. İnfeks Derg 2007;21:45-7.
12
Daldal A, Tekin-Koruk S, Çalışır C. Kırım Kongo Kanamalı Ateşi: Şanlıurfa’da ilk olgu. Klimik Derg 2012;25:44-6.
13
Sayıner HS, Şahin MS, Bıyık M, Selçuk MY, Aksöz S, Öznas O. Crimean-Congo haemorrhagic fever cases without travel history to endemic areas in Adıyaman. Klimik Derg 2017;30:142-5.
14
Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006;6:203-14.
15
Günaydın NS , Aydın K, Yılmaz G, Çaylan R, Köksal İ. Crimean-Congo hemorrhagic fever cases in the eastern Black Sea Region of Turkey: demographic, geographic, climatic, and clinical characteristics Turk J Med Sci 2010;40:829-34.
16
Kadanalı A, Erol S, Özkurt Z, Özden K. Epidemiological risk factors for Crimean-Congo hemorrhagic fever patients. Turk J Med Sci 2009;39:829-32.
17
Whitehouse CA. Risk groups and control measures for Crimean- Congo hemorrhagic fever. In: Ergonul O, Whitehouse CA, eds. Crimean-Congo Hemorrhagic Fever: A Global Perspective. Dordrecht (NL): Springer, 2007:273-80.
18
Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, ve ark. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002- 2007. Int J Infect Dis 2009;13:380-6.
19
Duru F, Fışgın T. Hematological aspects of Crimean-Congo hemorrhagic fever. Turk J Hematol 2009;26:161-6.
20
Bakır Ozbey S, Kader Ç, Erbay A, Ergönül Ö. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2014;14:300-2.
21
Dokuzoguz B, Kocagül Celikbas A, Gök SE, Baykam N, Eroglu MN, Ergönül Ö. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis 2013;57:1270-4.
22
Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res 1993;22:309-25.
23
Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989;41:581-5.
2024 ©️ Galenos Publishing House